TerminatedPhase 2NCT00180895

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Principal Investigator
Catherine Patte, MD, MD
Gustave Roussy, Cancer Campus, Grand Paris
Intervention
Rituximab(drug)
Enrollment
40 enrolled
Eligibility
20 years · All sexes
Timeline
2004

Study locations (1)

Collaborators

Hoffmann-La Roche

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00180895 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials